CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
COVID-19 Inpatient | COVID-19 Outpatient
What is the purpose of this trial?
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
- Ages18 years and older
- Trial withYale Cancer Center
- Start Date08/30/2020
- End Date01/30/2023
- Last Updated09/08/2020
- Study HIC#2000028181